Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-057458
Filing Date
2024-05-10
Accepted
2024-05-10 07:30:40
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20240331.htm   iXBRL 10-Q 2305696
2 EX-10.1 akro-ex10_1.htm EX-10.1 139354
3 EX-10.2 akro-ex10_2.htm EX-10.2 173802
4 EX-31.1 akro-ex31_1.htm EX-31.1 16151
5 EX-31.2 akro-ex31_2.htm EX-31.2 15893
6 EX-32.1 akro-ex32_1.htm EX-32.1 13335
  Complete submission text file 0000950170-24-057458.txt   9883215

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT akro-20240331.xsd EX-101.SCH 1302645
72 EXTRACTED XBRL INSTANCE DOCUMENT akro-20240331_htm.xml XML 1779618
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 24932897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)